SCHEMBL20501700

SCHEMBL20501700

N#CCC1CCC(C(=O)O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.54
PLAT P00750 1/20 0.54
LMNA P02545 1/20 0.54
ANPEP P15144 1/20 0.43
ENPEP Q07075 1/20 0.43
GABRP O00591 2/20 0.38
GABRD O14764 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB1 P18505 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRB2 P47870 2/20 0.38
GABRA4 P48169 2/20 0.38
GABRE P78334 2/20 0.38
GABRA6 Q16445 2/20 0.38
GABRG1 Q8N1C3 2/20 0.38
GABRG3 Q99928 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20501699 1.00 PLG (0.54) PLGPLATLMNAANPEPENPEP
SCHEMBL24228415 0.81 KMT2A (0.34) PLGPLATLMNAKMT2AALDH1A1
SCHEMBL8900253 0.81 SMN1; SMN2 (0.38) PLGPLATLMNAANPEPENPEP
SCHEMBL929414 0.80 PLG (0.56) PLGPLATLMNAANPEPENPEP
SCHEMBL3424858 0.80 PLG (0.56) PLGPLATLMNAANPEPENPEP
SCHEMBL7393783 0.80 PLG (0.35) PLGPLATLMNAANPEPGABRP
SCHEMBL2640157 0.78 PLG (0.54) PLGPLATLMNAANPEPENPEP
SCHEMBL13907209 0.78 JAK2 (0.33) KMT2AALDH1A1CYP3A4HSD11B1JAK2
SCHEMBL2162286 0.78 JAK2 (0.33) KMT2AALDH1A1CYP3A4HSD11B1JAK2
SCHEMBL24197645 0.78 JAK2 (0.33) KMT2AALDH1A1CYP3A4HSD11B1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3609888-B1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF LILLY CO ELI (US) 2025-08-27 EP disclosed
EP-4596041-A2 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Organovo, Inc. (US) 2025-08-06 EP disclosed
CN-110637015-B Fanisole X receptor agonist and application thereof 奥加诺沃公司 2024-04-02 CN disclosed
US-20220089575-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF ORGANOVO, INC. 2022-03-24 US disclosed
US-11236071-B1 Farnesoid X receptor agonists and uses thereof METACRINE, INC. (US) 2022-02-01 US disclosed
EP-3609888-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Metacrine, Inc. (US) 2020-02-19 EP disclosed
CN-110637015-A Farnesoin X receptor agonists and uses thereof 梅塔科林公司 2019-12-31 CN disclosed
WO-2018170182-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF METACRINE, INC. (US) 2018-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089575-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF NR1H4, NR1H2, NR1H3 PLG 2817/4885PLAT 1488/4885LMNA 1148/4885
US-11236071-B1 Farnesoid X receptor agonists and uses thereof NR1H4, NR1H2, NR1H3 PLG 2817/4885PLAT 1488/4885LMNA 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.